Patents by Inventor Antonio Morreale de León

Antonio Morreale de León has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED THIOLASES CAPABLE OF PRODUCING BRANCHED COMPOUNDS AND USES THEREOF
    Publication number: 20200270653
    Abstract: The invention relates to mutant thiolases capable of producing branched compounds which are considered of particular interest in industry. The invention also relates to method for obtaining said branched product.
    Type: Application
    Filed: December 29, 2016
    Publication date: August 27, 2020
    Applicant: REPSOL, S.A.
    Inventors: Vicente BERNAL SÁNCHEZ, Pamela TORRES SALAS, Antonio MORREALE DE LEÓN, Víctor BARRERA BURGOS, María del Mar GONZÁLEZ BARROSO, Fernando LÓPEZ GALLEGO, Federico GAGO BADENAS, Pedro Alejandro SÁNCHEZ MURCIA
  • Chromene derivatives
    Patent number: 9120764
    Abstract: Derivates of chromene of formula I, where the meanings for the various substituents are as indicated in the description. These compounds are useful as inhibitors of TCR-Nck interaction in T lymphocytes.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 1, 2015
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Balbino Jose Alarcon Sanchez, Angel Messeguer Peypoch, Antonio Morreale De Leon, Aldo Jorge Borroto Revuelta, Irene Azahara Arellano Rojo, Almudena Perona Requena, Esther Carrasco Romero
  • Drugs for inhibiting p38 and uses thereof
    Patent number: 9096554
    Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: August 4, 2015
    Assignee: UNIVERSIDAD AUTÓNOMA DE MADRID
    Inventors: Federico Mayor Menéndez, Cristina Murga Montesinos, Pedro Manuel Campos Muelas, Jacoba Johana Heijnen, Anna Maria Agnes Antonius Kavelaars, Antonio Morreale de León, Rubén Gil Redondo
  • DRUGS FOR INHIBITING P38 AND USES THEREOF
    Publication number: 20140296308
    Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 2, 2014
    Inventors: Federico Mayor Ménendez, Cristina Murga Montesinos, Pedro Manuel Campos Muelas, Jacoba Johana Heijnen, Anna Maria Agnes Antonius Kavelaars, Antonio Morreale de León, Rubén Gil Redondo
  • Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
    Patent number: 8785430
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: July 22, 2014
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypooh, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León, Maria Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria
  • CHROMENE DERIVATIVES
    Publication number: 20140005247
    Abstract: Derivates of chromene of formula I, where the meanings for the various substituents are as indicated in the description. These compounds are useful as inhibitors of TCR-Nck interaction in T lymphocytes.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 2, 2014
    Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Balbino Jose Alarcon Sanchez, Angel Messeguer Peypoch, Antonio Morreale De Leon, Aldo Jorge Borroto Revuelta, Irene Azahara Arellano Rojo, Almudena Perona Requena, Esther Carrasco Romero
  • Immunosuppressor based on the blockage of TCR-Nck interaction
    Patent number: 8614231
    Abstract: The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: December 24, 2013
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Balbino Alarcon Sanchez, Aldo Borroto Revuelta, Antonio Morreale de Leon, María del Carmen Fábregas Cleveria, Maria Luz Ortiz
  • Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
    Patent number: 8252786
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: August 28, 2012
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, legal representative, Ma Carmen Fabrega Claveria, legal representative, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León
  • IMMUNOSUPPRESSOR BASED ON THE BLOCKAGE OF TCR-NCK INTERACTION
    Publication number: 20120135041
    Abstract: The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction.
    Type: Application
    Filed: June 18, 2009
    Publication date: May 31, 2012
    Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Balbino Alarcon Sanchez, Angel Ramirez Ortiz, María del Carmen Fäbregas Cleveria, Maria Luz Ortiz, Aldo Borroto Revuelta, Antonio Morreale De Leon
  • COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
    Publication number: 20110160189
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Application
    Filed: March 7, 2007
    Publication date: June 30, 2011
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Angel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León